These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 37626310)
1. Intrinsic disorder in PRAME and its role in uveal melanoma. Antonietti M; Gonzalez DJT; Djulbegovic M; Dayhoff GW; Uversky VN; Shields CL; Karp CL Cell Commun Signal; 2023 Aug; 21(1):222. PubMed ID: 37626310 [TBL] [Abstract][Full Text] [Related]
2. Intrinsic disorder may drive the interaction of PROS1 and MERTK in uveal melanoma. Djulbegovic M; Taylor Gonzalez DJ; Antonietti M; Uversky VN; Shields CL; Karp CL Int J Biol Macromol; 2023 Oct; 250():126027. PubMed ID: 37506796 [TBL] [Abstract][Full Text] [Related]
3. Intrinsic Disorder in BAP1 and Its Association with Uveal Melanoma. Djulbegovic MB; Taylor DJ; Uversky VN; Galor A; Shields CL; Karp CL Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292588 [TBL] [Abstract][Full Text] [Related]
4. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663 [TBL] [Abstract][Full Text] [Related]
6. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176 [TBL] [Abstract][Full Text] [Related]
7. COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING. Alsoudi AF; Skrehot HC; Chévez-Barrios P; Divatia M; De La Garza M; Bretana ME; Schefler AC Retina; 2024 Sep; 44(9):1580-1589. PubMed ID: 39167579 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988 [TBL] [Abstract][Full Text] [Related]
9. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas. Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas. Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079 [TBL] [Abstract][Full Text] [Related]
12. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort. Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710 [TBL] [Abstract][Full Text] [Related]
13. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma. Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971 [TBL] [Abstract][Full Text] [Related]
14. Intrinsic disorder in proteins associated with oxidative stress-induced JNK signaling. Gehi BR; Gadhave K; Uversky VN; Giri R Cell Mol Life Sci; 2022 Mar; 79(4):202. PubMed ID: 35325330 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases. Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771 [TBL] [Abstract][Full Text] [Related]
16. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status. Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients. Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437 [TBL] [Abstract][Full Text] [Related]
18. Rapid prediction and analysis of protein intrinsic disorder. Dayhoff GW; Uversky VN Protein Sci; 2022 Dec; 31(12):e4496. PubMed ID: 36334049 [TBL] [Abstract][Full Text] [Related]
19. The dark proteome of cancer: Intrinsic disorderedness and functionality of HIF-1α along with its interacting proteins. Garg N; Kumar P; Gadhave K; Giri R Prog Mol Biol Transl Sci; 2019; 166():371-403. PubMed ID: 31521236 [TBL] [Abstract][Full Text] [Related]
20. Intrinsic Disorder in the Human Tear Proteome. Taylor Gonzalez DJ; Djulbegovic M; Antonietti M; Cordova M; Dayhoff GW; Mattes R; Galor A; Uversky VN; Karp CL Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):14. PubMed ID: 37561450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]